RAPP241220C17500
- 0.00
- 0.000.00%
Rapport Therapeutics Newsroom
Rapport Therapeutics (NASDAQ:RAPP) Is In A Strong Position To Grow Its Business
Jefferies Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $35
Rapport Therapeutics, Inc. (RAPP) Receives a Buy From Jefferies
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn
Rapport Therapeutics Management to Meet With Truist
Rapport Therapeutics Reports Correlation Between Seizure Biomarker, Clinical Seizures
Express News | Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in Rns Measured Long Episodes and Meaningful Reductions in Clinical Seizures
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
Promising Developments and Strategic Focus Bolster Buy Rating for Rapport Therapeutics
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Rapport Therapeutics, Inc. (RAPP) Gets a Buy From TD Cowen
Rapport Therapeutics | 10-Q: Quarterly report
Rapport Therapeutics Expects Cash to Fund Requirements Through 2026
Rapport Therapeutics Adds New Members to Board of Directors
Express News | Rapport Therapeutics Inc Q3 Shr View $-0.58 -- LSEG IBES Data
Rapport Therapeutics 3Q Loss/Shr 50c >RAPP
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Press Release: Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Express News | Johnson & Johnson Reports 6.8% Passive Stake in Rapport Therapeutics Inc as of Sept 30- SEC Filing